Unravel Data Launches Free Snowflake Native App for Cost and Performance Optimization on Snowflake Marketplace
Snowflake users can achieve actionable recommendations for cost and performance optimization with…
Parsable Recognized with Frost & Sullivan’s 2024 Global Enabling Technology Leadership Award for Redefining Manufacturing with Augmented Connected Worker Solutions
Parsable's mobile-first SaaS platform enables seamless digitization of manufacturing processes, offering real-time…
Clarivate Partners with CRKN to Further Canada’s Research Goals
Web of Science Provides Expanded Access to Essential Research Tools and Data…
Roches Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer
46% reduction in the risk of disease progression or death, and 27%…
adidas launches RS15 Avaglide A Rugby Boot built by and for Womens Rugby Players
RS15 Avaglide is a women’s specific boot, built to support the performance…
Colt, Honeywell and Nokia join forces to trial space-based quantum-safe cryptography
Press ReleaseColt, Honeywell and Nokia join forces to trial space-based quantum-safe cryptography…
Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response
Treatment with casdatifan, a HIF-2a inhibitor, plus cabozantinib, a tyrosine kinase inhibitor,…
New data show Roches Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer
The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than…
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde regimen in metastatic pancreatic adenocarcinoma
Phase III NAPOLI 3 trial is the largest and has the longest…
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33…